<?xml version='1.0' encoding='utf-8'?>
<document id="19331202"><sentence text="Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors."><entity charOffset="28-39" id="DDI-PubMed.19331202.s1.e0" text="vinorelbine" /><entity charOffset="44-53" id="DDI-PubMed.19331202.s1.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.19331202.s1.e0" e2="DDI-PubMed.19331202.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19331202.s1.e0" e2="DDI-PubMed.19331202.s1.e1" /></sentence><sentence text="Vinorelbine (VRL)-cisplatin (CDDP) is an active doublet for advanced non-small cell lung cancer"><entity charOffset="0-11" id="DDI-PubMed.19331202.s2.e0" text="Vinorelbine" /><entity charOffset="29-33" id="DDI-PubMed.19331202.s2.e1" text="CDDP" /><pair ddi="false" e1="DDI-PubMed.19331202.s2.e0" e2="DDI-PubMed.19331202.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19331202.s2.e0" e2="DDI-PubMed.19331202.s2.e1" /></sentence><sentence text=" CDDP has a narrow therapeutic index and may produce a cumulative nephrotoxicity over the treatment period"><entity charOffset="1-4" id="DDI-PubMed.19331202.s3.e0" text="CDDP" /></sentence><sentence text=" This study was to assess the risks of drug-drug interaction (DDI) over 3 consecutive cycles of VRL-CDDP combined treatments"><entity charOffset="100-103" id="DDI-PubMed.19331202.s4.e0" text="CDDP" /></sentence><sentence text="" /><sentence text="An open-label, nonrandomised, phase I study was carried out" /><sentence text=" Patients with normal hepatic/renal functions" /><sentence text=" D1: CDDP 100 mg/m2--D1, D8: oral VRL 60 mg/m2 q3w"><entity charOffset="5-8" id="DDI-PubMed.19331202.s8.e0" text="CDDP" /></sentence><sentence text=" Pharmacokinetics (PK) over the first 3 cycles" /><sentence text=" PK comparison between cycles and between study vs" /><sentence text=" literature" /><sentence text="" /><sentence text="Thirteen patients were evaluable for safety and PK" /><sentence text=" Adverse events were those frequently observed with CDDP or VRL, and consisted of hematological toxicities, nausea, vomiting and constipation"><entity charOffset="52-55" id="DDI-PubMed.19331202.s14.e0" text="CDDP" /></sentence><sentence text=" Concerning VRL and CDDP PK, no difference was detected between the 3 administrations nor between the study and reference values"><entity charOffset="20-23" id="DDI-PubMed.19331202.s15.e0" text="CDDP" /></sentence><sentence text="" /><sentence text="The absence of DDI between CDDP and oral VRL was demonstrated over 3 consecutive cycles of therapy"><entity charOffset="27-30" id="DDI-PubMed.19331202.s17.e0" text="CDDP" /></sentence><sentence text="" /></document>